Back to News
Market Impact: 0.15
Genprex, Inc. Announces Translational Analysis Results for Reqorsa from 11 Patients
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
Genprex announced findings from a translational analysis of patients treated with Reqorsa (quaratusugene ozeplasmid), its lead gene therapy candidate. The findings were presented at the Gerontological Society of America 2026 Annual Scientific Meeting; the provided article text does not report the results or any numerical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
GNPX0.35
More News
- Magnificent 7 loses $1 trillion. The most eye-popping stats from Thursday's tech stock plunge
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Wall Street’s best post-midterm rally in 44 years lasted just one day—then $3 trillion vanished as chip stocks plunged over AI fears
- AI stocks plunge after election, driving down US markets
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Shield AI To Hit $28.8 Billion Value With $5.3 Billion Radar Acquisition